[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV154 INTRANASALVACCINE: Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered 0.5ml of vaccine on day 0 and day 28 via intra-nasal route using a dropperControl Intervention1: COVAXIN\u00c2\u00ae: Whole-Virion Inactivated SARS-CoV-2 vaccine (COVAXIN\u00c2\u00ae) will be administered at day 0 and day 28 via intramuscular route.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV154 INTRANASALVACCINE: Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered 0.5ml of vaccine on day 0 and day 28 via intra-nasal route using a dropper", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: COVAXIN\u00c2\u00ae: Whole-Virion Inactivated SARS-CoV-2 vaccine (COVAXIN\u00c2\u00ae) will be administered at day 0 and day 28 via intramuscular route.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 185, "treatment_name": "Bbv154", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1387, "treatment_name": "Covaxin", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]